HM6: Real-world evidence and the use of big data for regulatory decision making; DARWIN EU


The session brought together perspectives, from both regulators and the pharmaceutical industry, on the potential that real-world evidence (RWE) can bring to the acknowledgement of the value of medicines post-marketing authorisation.

It is well recognised that as science advances and brings new treatments online, regulatory science must also evolve to make proper and rigorous assessments. Defining what is the right data to be generated, and enabling its use, by recognising its value is increasingly affecting the regulatory science agenda across the world. Eventually, such data can be used to support regulatory applications, leading to better decisions that could allow enhanced access from patients.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member